KBC Group
HZNP

KBC Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

KBC Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,794
Closed -$2.4M – 1932
2023
Q3 		$2.4M Sell
20,794
-63,015
-75% -$6.77M 0.01% 560
2023
Q2 		$8.62M Sell
83,809
-64,559
-44% -$6.81M 0.04% 380
2023
Q1 		$16.2M Sell
148,368
-146,104
-50% -$16.1M 0.07% 267
2022
Q4 		$33.5M Sell
294,472
-76,654
-21% -$6.37M 0.16% 145
2022
Q3 		$23M Buy
371,126
+11,554
+3% +$807K 0.12% 186
2022
Q2 		$28.7M Sell
359,572
-25,594
-7% -$2.42M 0.14% 173
2022
Q1 		$40.5M Buy
385,166
+112,292
+41% +$10.9M 0.16% 156
2021
Q4 		$29.4M Sell
272,874
-10,431
-4% -$1.14M 0.1% 212
2021
Q3 		$31M Buy
283,305
+120,309
+74% +$12.5M 0.11% 198
2021
Q2 		$15.3M Sell
162,996
-12,245
-7% -$1.13M 0.06% 303
2021
Q1 		$16.1M Buy
175,241
+77,858
+80% +$6.57M 0.07% 293
2020
Q4 		$7.12M Buy
97,383
+54,407
+127% +$4.04M 0.03% 401
2020
Q3 		$3.34M Buy
+42,976
New +$2.96M 0.02% 492

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

KBC Group's HZNP Position: Q4 2023 in Review

KBC Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 20,794 shares — an estimated $2.4M sold.

KBC Group first reported a position in HZNP in Q3 2020 and held it in 13 quarters. The position peaked at $40.5M in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • KBC Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • KBC Group sold 20,794 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.4M.
  • KBC Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 13 quarters.
  • KBC Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $40.5M in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on KBC Group's 13F filing for Q4 2023, filed 13 Feb 2024.